ID   SNU-638
AC   CVCL_0102
SY   SNU638
DR   BTO; BTO:0003478
DR   EFO; EFO_0006758
DR   ArrayExpress; E-MTAB-2706
DR   BioSample; SAMN03473180
DR   cancercelllines; CVCL_0102
DR   Cell_Model_Passport; SIDM01769
DR   CGH-DB; 127-1
DR   CGH-DB; 9015-4
DR   ChEMBL-Cells; CHEMBL3307747
DR   ChEMBL-Targets; CHEMBL614935
DR   Cosmic; 685583
DR   Cosmic; 848143
DR   Cosmic; 869511
DR   Cosmic; 921601
DR   Cosmic; 1067207
DR   Cosmic; 1090457
DR   Cosmic; 1294961
DR   Cosmic; 1528878
DR   Cosmic; 2036662
DR   Cosmic; 2373753
DR   Cosmic; 2484959
DR   Cosmic; 2646587
DR   Cosmic; 2807650
DR   DepMap; ACH-001664
DR   EGA; EGAS00001000610
DR   GEO; GSM1374896
DR   IARC_TP53; 7421
DR   KCLB; 00638
DR   PharmacoDB; SNU638_1476_2019
DR   PubChem_Cell_line; CVCL_0102
DR   Wikidata; Q54955236
RX   PubMed=9033653;
RX   PubMed=10812166;
RX   PubMed=10974411;
RX   PubMed=15723654;
RX   PubMed=19956504;
RX   PubMed=24807215;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=29435981;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: Seoul National University (SNU) cell line collection.
CC   Population: Korean.
CC   Doubling time: 25 hours (PubMed=29435981).
CC   HLA typing: A*03:19,24:02; B*44:02,52:01; C*05:01,12:02; DQB1*06:02,06:02; DRB1*15:01,15:01 (PubMed=25960936).
CC   HLA typing: A*03:19,24:02; B*44:02,52:01; C*05:01,12:02 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Asn375Ser (c.1124A>G); ClinVar=VCV000041611; Zygosity=Unspecified (PubMed=29435981).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Heterozygous (PubMed=9033653).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): DepMap; KCLB; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 10
ST   D16S539: 11,13 (KCLB; PubMed=25877200)
ST   D16S539: 11,13,14 (DepMap)
ST   D18S51: 14,16
ST   D21S11: 30.2,31
ST   D3S1358: 15
ST   D5S818: 10,13,14,15 (PubMed=25877200)
ST   D5S818: 10,13,14,15,16 (DepMap)
ST   D5S818: 10,14 (KCLB)
ST   D7S820: 9,10
ST   D8S1179: 11,13
ST   FGA: 17,26,27 (DepMap)
ST   FGA: 17,27 (PubMed=25877200)
ST   Penta D: 9
ST   Penta E: 14,18
ST   TH01: 7
ST   TPOX: 8,11
ST   vWA: 14,19
DI   NCIt; C4004; Gastric adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   48Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 34
//
RX   PubMed=9033653; DOI=10.1002/(SICI)1097-0215(19970207)70:4<443::AID-IJC12>3.0.CO;2-G;
RA   Park J.-G., Yang H.-K., Kim W.-H., Chung J.-K., Kang M.-S., Lee J.-H.,
RA   Oh J.H., Park H.-S., Yeo K.-S., Kang S.H., Song S.-Y., Kang Y.K.,
RA   Bang Y.-J., Kim Y.I., Kim J.-P.;
RT   "Establishment and characterization of human gastric carcinoma cell
RT   lines.";
RL   Int. J. Cancer 70:443-449(1997).
//
RX   PubMed=10812166; DOI=10.1016/S0165-4608(99)00217-4;
RA   Chun Y.-H., Kil J.-I., Suh Y.-S., Kim S.-H., Kim H., Park S.-H.;
RT   "Characterization of chromosomal aberrations in human gastric
RT   carcinoma cell lines using chromosome painting.";
RL   Cancer Genet. Cytogenet. 119:18-25(2000).
//
RX   PubMed=10974411; DOI=10.1016/s0304-3835(00)00535-8;
RA   Chung Y.M., Park S.-H., Park J.K., Kim Y.-T., Kang Y.-K., Yoo Y.D.;
RT   "Establishment and characterization of 5-fluorouracil-resistant
RT   gastric cancer cells.";
RL   Cancer Lett. 159:95-101(2000).
//
RX   PubMed=15723654; DOI=10.1111/j.1349-7006.2005.00016.x;
RA   Takada H., Imoto I., Tsuda H., Sonoda I., Ichikura T., Mochizuki H.,
RA   Okanoue T., Inazawa J.;
RT   "Screening of DNA copy-number aberrations in gastric cancer cell lines
RT   by array-based comparative genomic hybridization.";
RL   Cancer Sci. 96:100-110(2005).
//
RX   PubMed=19956504; DOI=10.4143/crt.2005.37.1.1;
RA   Ku J.-L., Park J.-G.;
RT   "Biology of SNU cell lines.";
RL   Cancer Res. Treat. 37:1-19(2005).
//
RX   PubMed=24807215; DOI=10.1038/ncomms4830;
RA   Liu J.-F., McCleland M.L., Stawiski E.W., Gnad F., Mayba O., Haverty P.M.,
RA   Durinck S., Chen Y.-J., Klijn C., Jhunjhunwala S., Lawrence M.,
RA   Liu H.-B., Wan Y.-N., Chopra V.S., Yaylaoglu M.B., Yuan W.-L., Ha C.,
RA   Gilbert H.N., Reeder J., Pau G., Stinson J., Stern H.M., Manning G.,
RA   Wu T.D., Neve R.M., de Sauvage F.J., Modrusan Z., Seshagiri S.,
RA   Firestein R., Zhang Z.-M.;
RT   "Integrated exome and transcriptome sequencing reveals ZAK isoform
RT   usage in gastric cancer.";
RL   Nat. Commun. 5:3830.1-3830.8(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=29435981; DOI=10.1002/ijc.31304;
RA   Kim H.J., Kang S.K., Kwon W.S., Kim T.S., Jeong I., Jeung H.-C.,
RA   Kragh M., Horak I.D., Chung H.C., Rha S.Y.;
RT   "Forty-nine gastric cancer cell lines with integrative genomic
RT   profiling for development of c-MET inhibitor.";
RL   Int. J. Cancer 143:151-159(2018).
//